← SGLT2 inhibitors × cardiovascular events

ArticleCardiovascular diabetology2023

Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.

Jui-Yi Chen et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 75,334 people · 2023

Not counted

Reduced deaths

−19%−31% to −4%

Bigger than 6 in 10 for all-cause mortality

As reported

RR 0.81, 95% CI 0.69–0.96 · the paper's word: All-cause mortality

Range includes no effect

No clear effect on cardiovascular events

−10%−20% to +1%

Bigger than 1 in 10 for cardiovascular events

As reported

RR 0.90, 95% CI 0.80–1.01

Not counted

Reduced cardiovascular events

−25%−42% to −2%

Bigger than 6 in 10 for cardiovascular events

As reported

RR 0.75, 95% CI 0.58–0.98

Three numbers in the abstract

the abstract, start to end

… users in DM population (RR: 0.81, 95% CI 0.69-0.96).

… HF (HHF) than dapagliflozin users (RR: 0.90, 95% CI 0.80-1.01).

… with those who used dapagliflozin (RR: 0.75, 95% CI 0.58-0.98).

← favours treatmentfavours comparator →
could be chance
All-cause mortality
RR 0.810.69–0.96
Cardiovascular events
RR 0.900.80–1.01
Cardiovascular events
RR 0.750.58–0.98
SGLT2 inhibitorsCardiovascular eventsAll-cause mortality
1 / 3

23 papers cite it

2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 37891550